Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 20,000 Class A shares of the company on 09/04/2024, with an aggregate market value of $120,800. These shares were originally acquired on 09/01/2016 as founders shares, a form of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 250,000 shares were sold for gross proceeds of $1,961,500.

Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 20,000 Class A shares of the company on 09/04/2024, with an aggregate market value of $120,800. These shares were originally acquired on 09/01/2016 as founders shares, a form of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 250,000 shares were sold for gross proceeds of $1,961,500.